What happens when cannabis meets cardio…
Right now, as I write this to you, scientists the world over are working fervently to harness the groundbreaking healing properties of cannabis into focused treatments for humanity’s most chronic ailments.
But there’s one cannabis pharmaceutical company whose groundbreaking discovery stands out among the crowd with the potential to revolutionize the way we treat the number one cause of death in America: heart disease.
The company might be tiny – its stock is trading for just $2 per share – but its profit potential is anything but.
Let me show you why.
Because while most cannabinoid-based medications are still in their early stages of development, this company’s CBD formulation is already undergoing Phase II clinical trials with the Food and Drug Administration (FDA) to receive approval to treat heart disease in high-risk COVID-19 patients, as well as acute myocarditis, the leading form of cardiac-related death among young people.
Heart failure affects more than 26 million people globally and has created a cardiovascular pharmaceutical market projected to hit $64 billion by 2026.
That means this company has the potential to disrupt a market even beyond the already massive demand for legal cannabis, which on its own could reach $51 billion by 2025…
And you have the chance to invest now while it’s still trading for $2 per share.
We have a special dossier on this company reserved for our NICI Membership subscribers.
In this dossier, you’ll hear about how the company’s plan to multiply your money with its revolutionary treatment for heart disease, including a full analysis of the company’s strengths, weaknesses, opportunities, and threats. Click here to unlock.
To your investing success,
Executive Director, National Institute for Cannabis Investors
December 08 2021